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Abstract
Osteonecrosis of the jaws is a clinical entity described and linked to treatment with bisphosphonates in 2003. Its 
real incidence is unknown and it could increase due to the large number of patients treated with these drugs, and its 
cumulative effect on the bone. State of the art knowledge regarding its etiopathogeny, clinical course and suitable 
treatments is limited.
Objectives: To study the clinical characteristics of 44 patients with bisphosphonate-related osteonecrosis of the jaws 
and the state of their bone mineral metabolism:  bone remodeling state, prevalence of fractures, bone mineral density 
study, and assessment of the different treatment strategies.
Design of the Study: Observational. Information was gathered prospectively through interviews, clinical examina-
tions, additional tests and review of medical records.
Results: We studied 16 men and 28 women with a mean age of 64.7 years. Breast cancer was the most frequent un-
derlying disease. Zoledronate was used in 82% of the cases and in the non-oncology group of patients; alendronate 
was the most frequently used bisphosphonate. The mean duration of the zoledronate and alendronate treatments was 
25 months and 88 months respectively. The lower jaw was the most frequent location, and previous exodontias—
among the triggering factors known—were the most closely linked to its onset. We found considerable osteoblastic 
activity in patients suffering from neoplasia, with artifacts present in their bone densitometry and a high percentage 
of vertebral fractures.
Conclusions: According to our results, osteonecrosis of the jaws affects elderly patients. We found a direct relation-
ship between the duration of exposure and the accumulated dose. Other relevant factors are: Poor oral and dental 
health, corticoids, diabetes and teeth extractions. In essence, it is a clinical diagnosis. Prevention is the best strategy 
to handle this clinical entity.
Key words: Alendronate, bisphosphonate, jaw, maxilla, osteonecrosis, osteoporosis, prevention, zoledronate.
Introduction
Bisphosphonates (BPs) are highly effective drugs to 
treat conditions associated to bone resorption increas-
es—these drugs were initially used for Paget’s disease 
and then for malignant hypercalcemia (MHC), multiple 
myeloma (MM), bone metastasis and osteoporosis. 
Bone in general is considered to be the third metastasis 
location. Using BPs—administered intravenously (IV) 
into the tumor bone diseased—is a leap forward taken 
in the last few years (1,2). Recently, using zoledronic 
acid in an annual, single dose has been added to the 
treatment of postmenopausal osteoporosis (3).
Oral BPs are the most thoroughly studied drugs to pre-
vent bone loss and reduce fractures.  Bone Mineral 
Density (BMO) increases mainly in the lumbar spine, 
but also in the proximal femur (4,5). 
BPs are well tolerated if administered correctly. In the 
last few years, a complication that had not been detect-
ed in previous clinical trials has been described: Os-
teonecrosis of the jaws (ONJ), which seems to be due to 
a combination of lack of vascular supply, lack of bone 
remodeling and regeneration (6). 
Its onset has been associated to many risk factors. The 
type, the administered dose and the administration 
route of the BP (7) have an impact. Duration of treat-
ment is an important factor as well, as are the presence 
of repeated traumatisms in the buccal mucosa, or prior 
dentoalveolar surgery (8-10). Additionally, diabetic pa-
tients, patients suffering from peripheral vascular dis-
eases, smokers, and patients receiving corticoids and/
or anti-neoplasic treatments concomitantly should be 
examined in greater detail (7,10).
Material and Methods
This study assesses all patients referred to the Stoma-
tology, Oral and Maxillofacial Surgery Department 
of the Insular Maternal and Child University Hospital 
Complex between March 2007 and December 2010, 
who were potentially suffering from BP-related ONJ, or 
presenting a dental pathology and long-term BP treat-
ment. We examined 70 patients and confirmed the ONJ 
diagnosis in 44 cases, which we selected as sample for 
our observational study. 
We applied the AAOMS inclusion criteria (11): 1. Cur-
rent or prior BP treatment; 2. Presence of exposed 
necrotic bone in the maxillofacial region for more than 
8 weeks; 3. No radiotherapy to the jaws; later modified 
by Bagán (12) to include the presence of fistulas, even 
without exposed necrotic bone, as an incipient ONJ 
stage. Patients with maxillary neoplasia were excluded.
After obtaining their consent for the study, patients 
answered to a general and dental health questionnaire, 
specially focused on risk factors, diseases and medica-
tions that could affect bone mineral metabolism.  
Analytics were requested with a focus on osteoporosis: 
hip and spine densitometry (DXA) and ultrasound of the 
calcaneus (QUS). Salivary pH was measured with Mach-
erey-Nagel ® test paper, the prevalence of cavities with 
the DMF index, gum’s health with the gingival index 
(GI), and the patient’s ability to remove bacterial plaque 
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with the Patient Hygiene Performance index (PHP). An 
orthopantomography and pictures were taken, and ad-
ditional tests were requested as needed (culture and/or 
biopsy, lateral spine radiographies of the dorsal-lumbar 
areas, bone gammagraphy and/or maxillary computeri-
zed tomography scan). Lastly, they were recommended 
pharmacological treatment, and based on the size and 
condition of their lesions, daily local cleansings were 
recommended, or other necessary treatments. They 
were given advice on oral and dental hygiene, healthy 
habits and recommendations on the dental, periodontal 
or prosthetic treatment they needed. 
Data were included in a Microsoft Excel ® spreadsheet 
and then imported to the statistical software SPSS ® 
(Statistical Package for the Social Sciences) for Windows, 
version 17. Seeking to compare some results, we divided 
our patients into three groups based on their underlying 
conditions (neoplasia, multiple myeloma or osteoporosis 
with rheumatoid arthritis); although we did not seek to 
obtain conclusive data, having disparate groups and a 
small sample size. The SNK (Student-Newman-Keuls) 
multiple comparison test was performed. 
Results
This study includes 44 patients in total, 16 men and 28 
women (Table 1).
#
CASES
GENDER BASELINE 
DISEASE
BISPHOSPHONATES TRIGGERING
FACTOR
LOCATION
14 Woman Breast 
Neoplasia
ZOL(12)
ZOL+IBN (2)
Exodontia (6)
Prosthesis (1)
Unknown (7)
Lower Jaw (9)
Upper Jaw (5)
6 Man Prostatic
Neoplasia
ZOL Exodontia (3)
Prosthesis (1)
Unknown (2)
Lower Jaw (5)
Upper Jaw (1)
1 Man Prostatic Neo.
Multiple My-
eloma
ZOL Unknown Lower Jaw
1 Man Prostatic Neo.
Renal Neo. 
ZOL Unknown Lower Jaw
10 Woman (5)
Man (5)
Multiple 
Myeloma
ZOL (5)
ZOL+PAM (3)
ZOL+PAM+CLD (1)
ZOL+PAM+ALN (1)
Exodontia (6)
Prosthesis (2)
Unknown (2)
Lower Jaw (9)
Upper Jaw (1)
6 Woman Osteoporosis ALN (4)
RSD (1)
ALN+RSD (1)
Exodontia (5)
Root canal treatment 
(1)
Lower Jaw (4)
Upper Jaw (2)
2 Woman Rheumatoid
 Arthritis
ALN Exodontia (1)
Torus (1)
Lower Jaw (1)
Lower+Upper Jaw (1)
1 Man Pulmonary 
Neoplasia
ZOL Exodontia Lower+Upper Jaw (1)
3 Woman (1)
Man (2)
Rectal 
Neoplasia 
ZOL (2)
ZOL+PAM (1)
Exodontia (2)
Unknown (1)
Lower Jaw
Table 1. Presentation of Clinical Cases.
Abbreviations: PAM: pamidronate; ZOL: zoledronate; ALN: alendronate; IBN: ibandronate; RSD: risedronate; CLD: clodronate.
Among the anthropometric baseline characteristics, the 
mean age, 64.2 years (41-82 years), is noteworthy. Re-
garding habits and lifestyle, 22% of the sample used to 
smoke (15 cigarettes/day on average for 28 years on ave-
rage) and 27% were ex smokers. We did not find regular 
intake of alcohol. Additionally, 52% did not exercise at 
all. Besides, 64% of patients had a daily calcium intake 
below 1200 mg; 55% of patients took calcium supple-
ments, with or without vitamin D. And 66% brushed 
their teeth more than once per day, whereas 21% did 
not brush their teeth. The most frequent concomitant 
diseases found were arterial hypertension (45%) and 
type II diabetes (35%). The most frequent concomitant 
treatments found were: Chemotherapy (81%), gastric 
protection (75%), tranquilizers (68%), corticoids (66%) 
and hormonal therapy (51%).
Zoledronate was used in 36 cases (82%) and in the 
non-oncology group of patients; alendronate was the 
most frequently used bisphosphonate (87.5%). The 
average duration of the zoledronate treatment was 25 
months (7-51 months); and of the alendronate treat-
ment, 88 months (32-176 months). The total dose 
taken by patients treated only with zoledronate was 
102 mg on average (36-204 mg), whereas those pa-
tients receiving only alendronate took 25,428 mg on 
average (8,960-51,970 mg). After confirming the ONJ 
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diagnosis, the BP treatment was stopped. We have 
found a triggering factor in all cases related to oral 
BPs. Broadly, the triggering factor is unknown in 
32% of the sample, and related to previous exodontias 
in 54.5% of the cases (Table 1).
Lesions were located in the lower jaw in 75% of the 
cases (Table 1), and duration-wise, the longest case is 
found in the superior maxilla—5.7 years at the conclu-
sion of the study. 
No patient had a full dentition, being the average DMF 
teeth value 13 in women, and 10 in men. They presented 
poor conservative dental treatment (16%), and widespread 
periodontal disease. The average GI in women was 1.9, 
and in men, 1.3; and the average PHP in women was 25%, 
and in men, 30%. Salivary pH was 6.5 on average. 
Figure 1 shows the first symptom or onset of this pa-
Fig. 1. First Symptom or Onset of this Pathology in our Patients.
thology in our patients. However, signs and symptoms 
most frequently found in the first visit were: Exposed 
bone (89%), inability to wear prosthesis (70%), suppu-
ration (61%), pain (59%), difficulty eating (52%), halito-
sis (50%), altered sensation of the jaw (45%), bone loss 
(41%), loose teeth (34%), mucous ulceration (34%), mu-
cous fistula (32%), tooth loss (23%), skin fistula (11%), 
oral-sinus communication (11%).
Regarding the biochemical values and hemogram, we 
must highlight glycemia levels above 110 mg/dL on 
average in the three groups of patients, and lower he-
moglobin (<12.0 g/dL) and hematocrit (<34%) values on 
average in the group of patients with neoplasia. Serum 
levels of calcium and phosphorus were normal. 
Table 2 shows the bone remodeling biochemical mark-
ers, divided into groups based on their main pathology. 
Biochemical
Marker
Reference 
Values 
Neoplasias
N= 26
Multiple 
Myeloma
N= 10
Osteoporosis
N= 8
Osteocalcin 15-46
(ng/mL)
27.4±25.6 14.2±8.7 10.3±3.5
P1NP < 37.1
(ng/mL)
89.8±110 31.8±24.4 19.1±7.3
Beta-Cross-
Lap
0-0.57/ 0- 0.3
(ng/mL)
0.52±0.82 0.20±0.12 0.18±0.13
TRAP 0.0-3.3
(U/L)
3.4±1.6 2.7±0.42 2.5±0.57
PTH 15-88
(pg/mL)
71.8±54 49.2±24.8 59.4±29.3
25-HCC 12.0-54.0 m. 23.2±9.3 33.4±9.4 24±10.8
Table 2. Bone-Remodeling Biochemical Markers, by Pathology. 
Bone Formation Markers (Osteocalcin; P1NP: Procollagen type-1 amino-terminal propeptide).  
Bone Resorption Markers (Beta-CrossLap: carboxy-terminal telopeptides of type 1 collagen; 
TRAP: Tartrate-resistant acid phosphatase). PTH: Parathyroid hormone; 25-HCC: vitamin D
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We linked lumbar spine, neck and hip total densitome-
tric values and ultrasounds of the calcaneus (QUS) to 
the pathologies, and compared the T-score (Table 3). 
N Average Standard 
Deviation
Standard 
Error
P Value*
T-score 
Spine
Neoplasias 26 1.13 2.67 0.59 0.122
M. Myeloma 10 0.37 2.16 0.76
Osteoporosis 8 -1.02 0.92 0.34
T-score
 Neck
Neoplasias 26 0.06 1.78 0.40 0.049
M. Myeloma 10 -1.30 1.23 0.40
Osteoporosis 8 -1.15 1.18 0.44
T-score 
Trochanter
Neoplasias 26 0.41 1.39 0.31 0.274
M. Myeloma 10 -0.19 1.28 0.42
Osteoporosis 8 -0.44 1.19 0.45
T-score 
Intertro-
chanter
Neoplasias 26 0.32 1.58 0.36 0.182
M. Myeloma 10 -0.55 1.29 0.43
Osteoporosis 8 -0.64 1.01 0.38
T-score 
Hip
Neoplasias 26 0.35 1.64 0.37 0.186
M. Myeloma 10 -0.54 1.30 0.43
Osteoporosis 8 -0.67 1.17 0.44
T-score 
QUS
Neoplasias 26 -0.92 1.31 0.31 0.353
M. Myeloma 10 -1.36 1.03 0.34
Osteoporosis 8 -1.60 0.38 0.14
Table 3. T-score Comparisons per Pathology.
* The p value has been obtained through the multiple comparison test SNK.
We found pathological vertebral fractures in the spine 
radiographies of the dorsal-lumbar area in 52% of the 
cases. Orthopantomographies (OPGs) showed radiolu-
cent images in relation to the ONJ lesion, and a diseased 
alveolar bone in 76% of the cases. The average size of 
the lesions measured in the 1st-visit OPG was 2.3 cm 
(1.2–4 cm).
Cultures were taken to perform antibiograms in 45% of 
the cases. Colonies of Streptococcus mitis and mille-
ri and Gram-negative microorganisms (Enterobacter 
cloacae, Prevotella spp, Fusobacterium spp) were the 
most frequently isolated. Biopsies were taken in 32% of 
the cases for further histological study of the lesions, or 
as a consequence of the surgical treatments applied. The 
regular pathological anatomy report was: Oral mucosa 
with epithelial hyperplasia, fibrosis and chronic inflam-
mation, along with necrotic bone tissue and acute in-
flammation and many Actinomyces bacterial colonies.
Full bone gammagraphy was undergone by 58% of pa-
tients, and an ONJ-compatible pathological captation 
was found in the upper or lower maxillas in 48% of the 
cases. The lower jaw gammagraphy was requested for 
37% of the patients. 
A computed axial tomography (CAT) scan was per-
formed in 34% of the cases to better assess the bone 
destruction and/or the diseased maxillary sinus.
The therapeutic approach was conservative: cycles of 
oral antibiotics and 0.12% clorhexidine (CHX) oral an-
tiseptic rinse in all cases. The most frequently used an-
tibiotics were amoxicillin/clavulanic (875/125mg-1000
/62.5mg) in 15 to 30-day cycles (92%). Other drugs used 
(depending on the clinical evolution, allergies or culture 
results) were: ciprofloxacin (26%), clindamycin (21%), 
metronidazole (16%), azithromycin (8%), spiramycin 
(8%) and in some cases: cloxacillin, ampicillin, penicil-
lin, rifampicin, fluconazole. Analgesics were used de-
pending on the pain and the main disease.
Serum, ciprofloxacin and hydrogel (Nu-Gel®) were 
used as cleansing treatments in 48% of patients. After 
2-3 weeks of such treatment, the extra-oral and oral fis-
tulas disappeared and suppurating oral lesions improved 
in all cases. Local surgical treatment was undergone by 
39% of patients, mainly alveolar curettage, and in some 
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cases (8%), sequestrectomy, alveolar segmental oste-
otomy and mucous flap of the ridge. For 21% of patients 
presenting small lesions (1.2-3 cm) without extra-oral 
fistulization, we added the local surgery treatment stra-
tegy (sequestrectomy and slight curettage of the under-
lying bone) and the use of autologous platelet concen-
trates enriched with growth factors (L-PRP) with the 
SmartPReP system by Harvest Corp (Plymouth, USA), 
done bilaterally in the lower jaw, in two cases. These 
patients improved in 2-4 weeks, their mouth lesions dis-
appeared and they continued to be asymptomatic for an 
average follow-up period of 14 months. 
There is a downward trend in the onset of new ONJ cases 
in our study. In 2007 we diagnosed 19 cases; in 2008, 11 
cases; in 2009, 8 cases; and in 2010, 6 cases. Because 
of their oncologic diseases, 32% of our patients have 
passed away, while 45% remain stable with no signs of 
infection, with or without exposed bone, and 23% still 
have signs of infection, despite the various pharmaco-
logical treatments received.
 
Discussion
ONJ is known as a devastating side effect of using BPs 
in the long-term, although in truth, the genesis of this 
entity has not been proven yet. Ever since it was des-
cribed for the first time in 2003 (8, 9), there have been 
more than 1,000 cases discussed in papers, editorials, 
letters to the editor and scientific congresses, regarding 
the strong association between ONJ and BPs (13-17), 
particularly among patients with MM or solid tumor 
bone metastases. These patients were generally treated 
with powerful BPs administered intravenously, but the 
number of osteoporosis patients with oral BP-related 
ONJ is increasing (18).
The action mechanism of BPs remains unclear. Being a 
drug that inhibits bone resorption, used to prevent and 
treat skeletal complications, why it is related to ONJ re-
mains hard to explain. The fact that the maxillas are the 
bones subject in the highest degree to bone remodeling, 
and that they are in direct contact with the mouth’s sep-
tic environment, could contribute to it (15).
In our study, the age range is similar to that of other se-
ries (19-21). Women are affected the most (64%) in line 
with the rest of publications (19,22); although men seem 
to be more affected in some series (20,21).
Zoledronate is the BP associated to ONJ most frequently 
(20-25). This could be due to the fact that it is a stronger, 
third generation BP used more and more frequently. Ca-
ses of oral BP-related ONJ are also being described in the 
literature and our own cases (18%)—specifically, alendro-
nate, ibandronate, risedronate or clodronate (8,9,18,24-
26). Alendronate is the one associated the most, probably 
because it has been the oral BP prescribed the most.
The most frequently found underlying disease has been 
breast carcinoma (32%), as in other series (15,19,22). 
However, MM is more frequent in other studies (23,25).
Regarding the duration of the exposure, it seems the 
risk of developing ONJ with intravenous BPs starts 
after 24 months of treatment, and increases after 36 
months (21). In our series, the average duration of treat-
ment with zoledronic acid only was 25 months (7-51 
months). However, oral BPs need more time and doses, 
due to their poor bioavailability. Therefore the risk in-
creases after 3 years (4). In our series, the average dura-
tion of treatment in alendronate-related cases is 7 years, 
although in risedronate-related cases it is 26 months, 
which makes us reflect upon the influence of the drug’s 
power in the onset of the lesions. 
ONJ has been recently described in patients treated 
with other anti-angiogenic and anti-osteoclastic acti-
vity agents similar to BPs, such as bevacizumab and de-
nosumab (27,28). For this reason Stopeck (28) already 
proposes using a more general term for this pathology: 
“drug-induced osteonecrosis of the jaws”.
Risk factors or co-factors associated to the physiopa-
thology of the ONJ—besides type, dose, duration of 
treatment and administration route—are very diverse 
(5,7). Then, lifestyle-related factors —tobacco, alcohol, 
inactivity, malnutrition, poor dental hygiene—have 
been described (11,18,23). In our patients, we have es-
tablished poor dental hygiene and significant tooth loss, 
either for lack of motivation or lack of financial re-
sources to have conservative dental treatments done.  In 
agreement with other authors (11,24), we believe there 
is a potential relationship between ONJ and corticoster-
oids treatment—in 66% of the cases in our series. In ad-
dition, as in some other papers (7,10,11), we believe dia-
betes to be an important co-morbidity factor. The most 
frequent maxillary location is the lower maxilla (75%), 
in agreement with the majority of authors. Exodontia 
prior to developing ONJ is the most important trigger-
ing factor known (54.5%); ranging from 38% (15) to 
86% (9) in other series. We found exposed bone in the 
first clinical examination in 89% of the cases, which 
was an important diagnosis criterion (9,14,18).
Among the bone remodeling biochemical markers, we ob-
serve very high osteocalcin and aminoterminal propeptid 
(P1NP) average values in the group of patients with neo-
plasia, compared to the group of patients with osteoporo-
sis, which indicates high osteoblastic activity in patients 
with neoplasia (particularly breast and prostate) possibly 
related to the bone metastasis. On a different note, sup-
pression of osteoclast activity is not appreciated in these 
same patients (Beta-CrossLaps, TRAP). The rest of the 
markers are within the normal ranges.
Regarding bone mineral density, we find very high hip 
and spine values in oncologic patients, which we sus-
pect could be affected by the baseline condition and 
the coexisting bone disease (pathological bone in MM, 
bone metastasis and fractures). The average T-score in 
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the neck is significantly higher in the group of patients 
with neoplasia (0.06 on average) compared to patients 
with MM and osteoporosis (p=0.049). However, ultra-
sound values, which could shed some light on the qua-
lity of the bone, actually show no significant differen-
ces. The prevalence of vertebral fractures in our series 
is high (52%), especially in the group of patients with 
MM (70%), although these patients are treated with 
very high doses of BPs. We do not have published stud-
ies to compare our results.
Managing these patients is very difficult. There are no 
standard treatments, and patients are weakened by se-
vere oncologic diseases—82% of the cases in our series. 
We agree with other authors (8,9,11,14,15) in that the 
conservative or minimally aggressive treatment seems 
to be the most recommendable course of action. For 
patients with ONJ and skin fistulas we discussed in a 
recent paper (29) a conservative treatment based on lo-
cal cleansing treatments, which is useful, until a definite 
treatment can be performed. In this series, it is applied 
to all patients with oral or extra-oral fistulization (48%), 
which yielded considerable clinical improvement. 
Adornato and cols. (30) publish good results by adding 
to the local surgical treatment a platelet concentrate en-
riched with growth factors. L-PRP (leukocytes-platelet-
rich plasma) was applied in our series. This type of plate-
let concentrate has potential effects on proliferation, dif-
ferentiation, immunity and infection, and it favors posi-
tive results when treating these lesions surgically.
BPs are not metabolized. They may remain in the bone 
for a long time after drug suppression. Therefore, some 
authors (5,15,20) consider that stopping the BP treatment 
does not seem to avoid the onset or accelerate the reco-
very from ONJ . In our series, we have observed clini-
cal improvement in 66% of the cases after stopping the 
BP treatment, and in oral BP-related cases, 71% showed 
improvement after 5 months on average (4-7 months), in 
agreement with other authors (8,9). 
Due to the complexity of the treatment, our main goal is 
prevention and the correct information of patients, and 
just like other authors (9,10,13-15), we believe prevention 
and health and dental care coordination are essential in 
preventing the onset. However, there are no systemic 
oral or patient indicators so far to predict what patients 
will develop ONJ due to surgical dental treatments. Pos-
sibly, the progressive decline detected in the onset of 
new cases of ONJ is due to the better understanding of 
this pathology and the prevention measures adopted, 
both for patients who are about to start an intravenous 
BP treatment as for those already receiving it, and also 
for patients subject to long term oral BP treatments. 
These patients undergo regular check ups of their oral 
cavities, their dental and/or prosthesis treatment needs 
are assessed and we provide them with the guidelines 
necessary to correctly complete treatments.
References 
1. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J 
Clin Invest. 1996;97:2692-6.
2. Body JJ, Bergmann P, Boonen S, Boutsen Y, Devogelaer JP, Goe-
maere S, et al. Management of cancer treatment-induced bone loss in 
early breast and prostate cancer - a consensus paper of the Belgian 
Bone Club. Osteoporos Int. 2007;18:1439-50.
3. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trech-
sel U, et al. Intravenous zoledronic acid in postmenopausal women 
with low bone mineral density. N Engl J Med. 2002;346:653-61.
4. Delmas PD. The use of bisphosphonates in the treatment of oste-
oporosis. Curr Opin Rheumatol. 2005;17:462-6.
5. Watts NB. Bisphosphonate treatment of osteoporosis. Clin Geriatr 
Med. 2003;19:395-414. 
6. Jiménez-Soriano Y, Bagan JV. Bisphosphonates, as a new cause of 
drug-induced jaw osreonecrosis: an update. Med Oral Patol Oral Cir 
Bucal 2005;10:e88-91. 
7. Shane E, Goldring S, Christakos S, Drezner M, Eisman J, Silver-
man S et al. Osteonecrosis of the jaw: more research needed. J Bone 
Miner Res. 2006;21:1503-5.
8. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) in-
duced avascular necrosis of the jaws: a growing epidemic. J Oral 
Maxillofac Surg. 2003;61:1115-18. 
9. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecro-
sis of the jaws associated with the use of bisphosphonates: a review 
of 63 cases. J Oral Maxillofac Surg. 2004;62:527-34.
10. Estefanía R, Ponte R, Aguirre JM. Bisphosphonates and oral pa-
thology II. Osteonecrosis of the jaws: review of the literature before 
2005. Med Oral Patol Oral Cir Bucal. 2006;11:e456-61. 
11. Advisory Task Force on Bisphosphonate-Related Osteonecrosis 
of the Jaws, American Association of Oral and Maxillofacial Sur-
geons. American Association of Oral and Maxillofacial Surgeons 
position paper on bisphosphonate-related osteonecrosis of the jaws. J 
Oral Maxillofac Surg. 2007;65:369-76.
12. Bagan JV, Jimenez Y, Diaz JM, Murillo J, Sanchis JM, Poveda R, 
et al. Osteonecrosis of the jaws in intravenous bisphosphonate use: 
Proposal for a modification of the clinical classification. Oral Oncol. 
2009;45:645-6. Epub 2008 Aug 19.
13. Hellstein JW, Marek CL. Bisphosphonates osteochemonecrosis 
(bis-phossy jaw): is this phossy jaw of the 21 st century? J Oral Max-
illofac Surg. 2005;63:682-9.
14. Bagan J, Blade J, Cozar JM, Constela M, García Sanz R, Gómez 
Veiga F, et al. Recommendations for the prevention, diagnosis, and 
treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated 
with bisphosphonates. Med Oral Patol Oral Cir Bucal. 2007;12:E336-
40.
15. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bi-
sphosphonate-associated osteonecrosis of mandibular and maxillary 
bone: an emerging oral complication of supportive cancer therapy. 
Cancer. 2005;104:83-93.
16. Mehrotra B, Ruggiero S. Bisphosphonate complications includ-
ing osteonecrosis of the jaw. Hematology Am Soc Hematol Educ 
Program. 2006:356-60,515. 
17. Maerevoet M, Martin C, Duck L.Osteonecrosis of the jaw and 
bisphosphonates. N Engl J Med. 2005;353:99-102; discussion 99-102. 
Erratum in: N Engl J Med. 2005;353:2728. 
18. Yarom N, Elad S, Madrid C, Migliorati CA. Osteonecrosis of the 
jaws induced by drugs other than bisphosphonates - a call to update 
terminology in light of new data. Oral Oncol. 2010;46:e1.
19. Bagan JV, Jiménez Y, Murillo J, Hernández S, Poveda R, Sanchis 
JM, et al. Jaw osteonecrosis associated with bisphosphonates: mul-
tiple exposed areas and its relationship to teeth extractions. Study of 
20 cases. Oral Oncol. 2006;42:327-9.
20. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Ra-
poport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T. Os-
teonecrosis of the jaw in multiple myeloma patients: clinical features 
and risk factors. J Clin Oncol. 2006;24:945-52.
21. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopou-
los I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treat-
Med Oral Patol Oral Cir Bucal. 2012 Nov 1;17 (6):e948-55.                                                                                                                                                            44 cases of osteonecrosis of the jaws   
e955
ment with bisphosphonates: incidence and risk factors. J Clin Oncol. 
2005;23:8580-7.
22. Dore F, Filippi L, Biasotto M, Chiandussi S, Cavalli F, Di Lena-
rda R. Bone scintigraphy and SPECT/CT of bisphosphonate-induced 
osteonecrosis of the jaw. J Nucl Med. 2009;50:30-5.
23. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and 
bisphosphonates.N Engl J Med. 2005;353:99-102.
24. Kos M, Kuebler JF, Luczak K, Engelke W. Bisphosphonate-relat-
ed osteonecrosis of the jaws: a review of 34 cases and evaluation of 
risk. J Craniomaxillofac Surg. 2010;38:255-9.
25. Favia G, Pilolli GP, Maiorano E. Histologic and histomorphomet-
ric features of bisphosphonate-related osteonecrosis of the jaws: an 
analysis of 31 cases with confocal laser scanning microscopy. Bone. 
2009;45:406-13.
26. Bocanegra-Pérez S, Vicente-Barrero M, Sosa-Henríquez M, Ge-
baguer Blanco A, Knezevic M, Castellano-Navarro JM. Osteonecro-
sis maxilar secundaria al uso de bisfosfonatos por vía oral. Expos-
ición de tres casos clínicos relacionados con alendronato. Rev Med 
Chil. 2009;137:271-5.
27. Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini 
JP, Gulley JL, et al. Higher incidence of Osteonecrosis of the Jaw 
(ONJ) in patients with metastatic castration resistant prostate cancer 
treated with anti-angiogenic agents. Cancer Invest. 2009;27:221-6.
28. Stopeck A. Denosumab findings in metastatic breast cancer. Clin 
Adv Hematol Oncol. 2010;8:159-60.
29. Pérez SB, Barrero MV, Hernández MS, Knezevic M, Navarro 
JM, Millares J. Bisphosphonate-associated osteonecrosis of the jaw. 
A proposal for conservative treatment. Med Oral Patol Oral Cir Bu-
cal. 2008;13:E770-3.
30. Adornato MC, Morcos I, Rozanski J. The treatment of bisphos-
phonate associated osteonecrosis of the jaws with bone resection 
and autologous platelet-derived growth factors. J Am Dent Assoc. 
2007;138:971-7.
